id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0923-0006,FDA,FDA-2025-E-0923,Determination of Regulatory Review Period for Purposes of Patent Extension; ROMVIMZA,Notice,Determinations,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,2026-02-28T04:59:59Z,2025-12-29T19:54:00Z,2025-23862,0,0,09000064b910a397
FDA-2025-E-0923-0005,FDA,FDA-2025-E-0923,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-08-19T04:00:00Z,2025,8,2025-08-19T04:00:00Z,,2025-08-19T21:38:13Z,,0,0,09000064b8f079d9
FDA-2025-E-0923-0004,FDA,FDA-2025-E-0923,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-07-15T04:00:00Z,2025,7,2025-07-15T04:00:00Z,,2025-07-15T19:46:32Z,,0,0,09000064b8e6f0f3
FDA-2025-E-0923-0003,FDA,FDA-2025-E-0923,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-06-30T04:00:00Z,2025,6,2025-06-30T04:00:00Z,,2025-06-30T16:37:52Z,,0,0,09000064b8e457d5
FDA-2025-E-0923-0002,FDA,FDA-2025-E-0923,Patent Extension Application from Goodwin Procter LLP (on behalf of Deciphera Pharmaceuticals LLC),Other,Application,2025-03-26T04:00:00Z,2025,3,2025-03-26T04:00:00Z,,2025-03-26T18:19:25Z,,0,0,0900006486a3d288
FDA-2025-E-0923-0001,FDA,FDA-2025-E-0923,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-03-26T04:00:00Z,2025,3,2025-03-26T04:00:00Z,,2025-03-26T18:19:19Z,,0,0,0900006486a3d286